Skip to Content

Evaluation of the Pharmaceuticals Industry Investment Program

Submissions

* Submissions marked with an asterisk have omitted 'In confidence' content - part or all of the submission is not online.

# Hash denotes some attachments are not available online. Contact the project team for access if necessary.

% Percent symbol denotes scanned image PDFs which are not readable by some screen readers. For help read our accessibility statement.

Copyright in submissions resides with the author(s), not with the Productivity Commission.

All submissions will remain on the Commission's website indefinitely.


No. Individual / Organisation Date Pages File/s
1
Association of Australian Medical Research Institutes
16/09/2002 2
2
Merck Sharp & Dohme (Australia) Pty Limited
14/10/2002 9
3
Department of Innovation, Industry and Regional Development
04/11/2002 25
4
Mayne Pharma *
06/11/2002 23   
8
Industry Tourism Resources
15/01/2003 9
9
Eli Lilly Australia Pty Limited
15/01/2003 20
10
Medicines Australia
15/01/2003 49
11
Merck Sharp & Dohme
16/01/2003 37
12
Pfizer
30/01/2003 37
13
CSL limited
16/01/2003 2
14
Ausbiotech
16/01/2003 8
15
Victoria University
17/01/2003 15
16
Department of State and Regional Development
17/01/2003 5
17
Bristol-Myers Squibb Australia Pty Ltd *
20/01/2003 22   
18
ARI (ANSTO)
30/01/2003 3